@article{730497f69c284d26bb6f48baaaf844bf,
title = "Do CARs finally hit the CLL road?",
author = "Kater, {Arnon P.} and Melenhorst, {J. Joseph}",
note = "Funding Information: Conflict-of-interest disclosure: A.P.K. received consultancy fees from Abbvie, Janssen, Astra Xeneca, BMS, Roche, LAVA; speakers fee from Abbvie; and research funding from Janssen, Abbvie, Astra Zeneca, BMS, Celgene, and Roche. J.J.M. received consultancy fees from Shanghai Unicar-Therapy Bio-medicine Technology Co, Ltd, Simcere of America Inc, IASO Biotherapeutics, Co Ltd, Poseida Therapeutics, Janssen Research & Development, LLC; research funding from Incyte, Parker Institute for Cancer Immunotherapy, and Novartis; and served on the advisory board for IASO Biotherapeutics.",
year = "2022",
month = mar,
day = "24",
doi = "https://doi.org/10.1182/blood.2021014492",
language = "English",
volume = "139",
pages = "1775--1776",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",
}